NCT07072208View on ClinicalTrials.gov

Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL

NARecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2027

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Induction therapy-Pro regimen

"Pro regimen induction(21days per cycle\*1 cycle)~* Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle~* Rituximab 100mg per vial 375mg/m2, intravenous drip, Day 1 of each cycle~* Orelabrutinib 50mg per tablet 150mg orally per day from Days 1 to 21 of each cycle"

DRUG

Consolidation therapy-Pro-pola regimen

Pro-pola regimen consolidation(21days per cycle\*6 cycle) -Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle -Rituximab 100mg per vial 375mg/m2, intravenous drip, Day 1 of each cycle -Orelabrutinib 50mg per tablet 150mg orally per day from Days 1 to 21 of each cycle -Polatuzumab vedotin 30mg per vial 1.8 mg/kg, intravenous drip, Day 1 of each cycle

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER